DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
BGB-A317 is an investigational drug.
There have been 59 clinical trials for BGB-A317. The most recent clinical trial was a Phase 1 trial, which was initiated on January 25th 2017.
The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Neoplasms. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and Celgene.
There are two US patents protecting this investigational drug.
Recent Clinical Trials for BGB-A317
|Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma||National Taiwan University Hospital, Yun-Lin Branch||Phase 2|
|Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma||National Taiwan University Hospital||Phase 2|
|Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation||German CLL Study Group||Phase 2|
Top disease conditions for BGB-A317
Top clinical trial sponsors for BGB-A317
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|BGB-A317||Start Trial||Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment||Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ)||Start Trial|
|BGB-A317||Start Trial||Combination therapy with an anti-axl antibody-drug conjugate||ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|